News

US-based Merck and Schering-Plough, and their cholesterol JV, Merck/Schering-Plough Pharmaceuticals (MSP) have signed an agreement to resolve the civil class action litigation for $41.5 million. The lawsuit, currently

Law firm, Shalov Stone Bonner & Roccohas has filed a lawsuit seeking a class action status (on behalf of purchasers of the securities of Caraco) in US District

GeoVax has provided updates on its ongoing and planned human clinical trials – Phase 2a Preventive and Phase 1 Therapeutic (in the planning stage). The Preventative trial, designated

Anesiva and Arcion have signed a definitive merger agreement. The merger is likely to result in a public company with a portfolio of late-stage targeted pain therapeutics. The

Baxter has completed production of its first commercial batches of celvapan A/H1N1 pandemic vaccine, and is discussing plans for distribution with national health authorities. Baxter plans to deliver

Novavax has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus, under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville.

Labopharm has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada, for its novel formulation of the antidepressant – trazodone. The company’s NDS

EpiCept has filed a New Drug Submission (NDS) with Health Canada for Ceplene (histamine dihydrochloride), for the treatment of acute myeloid leukemia (AML) patients in first complete remission.

NeurogesX has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new